Epistem Holdings' (LON:EHP) new chief executive is to join six weeks earlier than planned.
David Budd will now take over on 1 March instead of the middle of April as previously anticipated.
Budd has more than 20 years of international commercial and operational experience in diagnostics and medical devices, especially in the molecular field.
He joins from Danaher subsidiary Leica Biosystems where he was last post was general manager of Leica Biosystems Amsterdam.
At Leica Biosystems Newcastle, he had global responsibility for marketing, market research and product launches for diagnostic tests.
Epistem revealed yesterday its genedrive diagnostic test had been cleared for European clinical trials in Hepatitis C (HCV) by the Institut Pasteur in Paris.
Genedrive was launched to test for TB in India last year.
Budd said: “I believe Genedrive is an outstanding molecular diagnostic system with significant near term commercial opportunities in tuberculosis testing and across a wide range of other applications in the future.”